Seres Therapeutics, Inc. — fact timeline

Seres Therapeutics, Inc. amended Lease Amendment with 101 CPD LLC valued at approximately $33.9 million (effective 2026-06-04).

“On June 4, 2026, the Company entered into the First Amendment to Lease (the “Lease Amendment”) with 101 CPD LLC (f/k/a HCP/King 101 CPD LLC), a Delaware limited liability company (the “Landlord”), which amends the Lease Agreement, dated September 22, 2021, by and between the Company and the Landlord (as amended, the “Lease”), pursuant to which the Company leases approximately 82,714 rentable square feet of office and laboratory space located at 101 CambridgePark Drive, Cambridge, Massachusetts (the “Existing Premises”).”

Seres Therapeutics, Inc. amended APA Amendment with Société des Produits Nestlé S.A. valued at $25.0 million (effective 2026-06-02).

“On June 2, 2026, Seres Therapeutics, Inc. (the “Company”) entered into Amendment No. 1 (the “APA Amendment”) to the Asset Purchase Agreement, dated as of August 5, 2024 (as previously amended by that certain Letter Agreement, dated September 30, 2024 and that certain Letter Agreement, dated December 31, 2024, the “Purchase Agreement”), by and between the Company and Société des Produits Nestlé S.A., a société anonyme organized under the laws of Switzerland (“SPN”).”

Hans-Juergen Woerle resigned as member of the board of directors at Seres Therapeutics, Inc..

“On May 30, 2026, Hans-Juergen Woerle, M.D., Ph.D. resigned from his position as a member of the board of directors of Seres Therapeutics, Inc. (the “Company”) and on the committees on which he serves, effective May 31, 2026.”

Seres Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $19.9 million for the first quarter of 2026.

“Seres Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 and provided operational updates.”

Seres Therapeutics, Inc. reported the full year 2025 results: net income Net income from continuing operations was $5.7 million.

“Net income from continuing operations was $5.7 million for the full year 2025, as compared to a net loss from continuing operations of $125.8 million for 2024.”

Seres Therapeutics, Inc. reported the fourth quarter of 2025 results: net income Net loss from continuing operations was $15.3 million.

“Net loss from continuing operations was $15.3 million for the fourth quarter of 2025, as compared to a net loss from continuing operations of $15.7 million for the same period in 2024.”

Seres Therapeutics, Inc.: Effected a 1-for-20 reverse stock split of common stock by filing a Certificate of Amendment to the Restated Certificate of Incorporation (effective 2025-04-21).

“On April 21, 2025, Seres Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Restated Certificate of Incorporation (the “Charter Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), effective April 21, 2025 at 5:00 p.m., Eastern Time (the “Effective Time”).”

Lisa von Moltke resigned as Executive Vice President and Chief Medical Officer at Seres Therapeutics, Inc..

“On February 22, 2025, Lisa von Moltke, M.D. notified Seres Therapeutics, Inc. (the “Company”) of her intention to resign as the Executive Vice President and Chief Medical Officer of the Company, effective as of March 14, 2025.”

Hans-Juergen Woerle, M.D. was appointed as Class III director at Seres Therapeutics, Inc..

“appointed Hans-Juergen Woerle, M.D., as a Class III director of the Company, effective immediately.”

Seres Therapeutics, Inc. completed a disposition involving Société des Produits Nestlé S.A. for $100.0 million, less approximately $17.9 million owed by Seres to an affiliate of SPN as of March 31, 2024 under the existing license agreement between Seres an (closed 2024-09-30).

“On September 30, 2024, Seres completed the previously announced sale (the “ Transaction ”) of the VOWST Business, including inventory and equipment, certain patents and patent applications, know-how, trade secrets, trademarks, domain names, marketing authorizations and related rights, documents, materials, business records and data and contracts that are used or held for use primarily in the development, commercialization and manufacturing of the microbiome product sold under the brand name VOWST as provided for in accordance with the terms of the Purchase Agreement (the “ Product ”), pursuant to the Asset Purchase Agreement, dated as of August 5, 2024 (the “ Purchase Agreement ”), by and among the Company and SPN, and a wholly-owned subsidiary of Nestlé S.A.”

Seres Therapeutics, Inc. reported first quarter 2024 results: revenue $10.1 million, net income $40.1 million.

“BUSINESS UPDATES Continued market adoption of VOWST ® with approximately 1,411 patient enrollment forms received, approximately 1,083 new patient starts, and net sales of $10.1 million during Q1 2024, and accelerated net sales in March and April SER-155 Phase 1b placebo-controlled Cohort 2 clinical readout expected end of Q3 2024 Further microbiome therapeutic”

Seres Therapeutics, Inc. reported a default on term loan of $110.0 million currently outstanding with Oaktree Fund Administration, LLC at three-month term Secured Overnight Financing Rate (“SOFR”) (subject to a 2.50% f maturing April 27, 2029.

“The Oaktree Credit Agreement establishes a term loan facility (the “Term Loan”) of up to $250.0 million with a maturity date of April 27, 2029 (the “Maturity Date”), of which $110.0 million is currently outstanding. Borrowings under the Term Loan bear interest at a rate per annum equal to the three-month term Secured Overnight Financing Rate (“SOFR”) (subject to a”

Seres Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“April 19, 2024, Seres Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”), had closed below the $1.00 per share minimum bid price requirement for continued inclusion on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). The letter has no immediate effect on the listing of the Common Stock on T”

Seres Therapeutics, Inc.: Increased authorized shares of Common Stock from 240,000,000 to 360,000,000 (effective 2024-04-05).

“On April 4, 2024, Seres Therapeutics, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”), at which the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of the Company’s Common Stock, $0.001 par value per share, from 240,000,000 shares to 360,000,000 shares, as described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on March 5, 2024. The Company’s board of directors previously approved the Amendment and, on April 5, 2024, the Company filed a Certificate of Amendment to the Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to effect the Amendment, which became effective upon filing with the Secretary of State.”

Seres Therapeutics, Inc. shareholders approved A stockholder proposal on Simple Majority Vote at the 2024-04-04 meeting.

“Item 6 – A stockholder proposal on Simple Majority Vote.”

Seres Therapeutics, Inc. shareholders approved Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes at the time of the Annual Meeting to approve Item 4 at the 2024-04-04 meeting.

“Item 5 - Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes at the time of the Annual Meeting to approve Item 4.”

Seres Therapeutics, Inc. shareholders approved Approval of an amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 240,000,000 to 360,000,000 shares at the 2024-04-04 meeting.

“Item 4 - Approval of an amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 240,000,000 to 360,000,000 shares.”

Seres Therapeutics, Inc. shareholders approved Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers at the 2024-04-04 meeting.

“Item 3 - Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers.”

Seres Therapeutics, Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024 at the 2024-04-04 meeting.

“Item 2 - Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024.”

Seres Therapeutics, Inc. shareholders approved Election of two Class III directors to serve until the 2027 Annual Meeting of Stockholders at the 2024-04-04 meeting.

“Item 1 - Election of two Class III directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.”

Seres Therapeutics, Inc. reported quarter and year ended December 31, 2023 results: revenue $10.4 million, net income $41.2 million.

“Seres reported a net loss of $41.2 million for the fourth quarter of 2023, as compared to a net loss of $68.8 million for the same period in 2022. Net sales of VOWST for the fourth quarter and full year 2023, were $10.4 million and $19.6 million, respectively”

David Arkowitz retired as Chief Financial Officer at Seres Therapeutics, Inc..

“Mr. Arkowitz’s retirement effective as of March 15, 2024 (the “Retirement Date”).”

Marella Thorell was appointed as Executive Vice President and Chief Financial Officer at Seres Therapeutics, Inc..

“On February 24, 2024, the Board of Directors (the “Board”) of Seres Therapeutics, Inc. (the “Company”) appointed Marella Thorell to succeed David Arkowitz as the Company’s Executive Vice President and Chief Financial Officer, effective as of the commencement of her employment with the Company, which is expected to be on or about March 25, 2024 (the “Effective Date”), following Mr. Arkowitz’s retirement effective as of March 15, 2024 (the “Retirement Date”).”

Seres Therapeutics, Inc. reported the fourth quarter of 2023 results: revenue net sales of VOWST of approximately $10.4 million (unaudited).

“On January 9, 2024, Seres Therapeutics, Inc. (the “Company”) issued a press release in which the Company announced, among other things, that based on preliminary financial results, the Company had net sales of VOWST of approximately $10.4 million (unaudited) in the fourth quarter of 2023, and preliminary cash, cash equivalents and investments of approximately $128 million (unaudited) as of December 31, 2023.”

Seres Therapeutics, Inc.: Adopted Amended and Restated Bylaws with changes to proxy rules, stockholder nominations, and technical updates (effective 2024-01-02).

“On January 2, 2024, the Board of Directors (the “ Board ”) of Seres Therapeutics, Inc., a Delaware corporation (the “ Company ”) approved and adopted the Company’s Amended and Restated Bylaws (the “ Amended and Restated Bylaws ”), which became effective the same day.”

Seres Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income net loss of $47.9 million.

“Seres reported a net loss of $47.9 million for the third quarter of 2023, as compared with a net loss of $60.0 million for the same period in 2022.”

Grégory Behar resigned as director at Seres Therapeutics, Inc..

“On October 2, 2023, Grégory Behar informed Seres Therapeutics, Inc. (the “Company”) of his resignation from the board of directors of the Company, effective immediately, in connection with his resignation from Nestlé Health Science.”

Seres Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.

“On August 8, 2023, Seres Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended June 30, 2023 and provided operational updates.”

Seres Therapeutics, Inc. reported financial results for First Quarter 2023.

“Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2023 financial results and provided business updates.”

Seres Therapeutics, Inc. entered into Credit Agreement with Oaktree Fund Administration, LLC, as administrative agent, and the lenders from time to time party thereto valued at $250 million (effective 2023-04-27).

“On April 27, 2023 (the “Closing Date”), Seres Therapeutics, Inc., a Delaware corporation (the “Company”) entered into a Credit Agreement and Guaranty (the “Credit Agreement”), among the Company, the subsidiary guarantors from time to time party thereto, the lenders from time to time party thereto (the “Lenders”), and Oaktree Fund Administration, LLC, in its capacity as administrative agent for the Lenders (in such capacity, the “Agent”).”

Seres Therapeutics, Inc. reported financial results for quarter and year ended December 31, 2022.

“On March 7, 2023, Seres Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2022 and provided operational updates.”

Claire Fraser was appointed as Class II Director at Seres Therapeutics, Inc..

“On January 4, 2023, the Board of Directors (the “Board”) of Seres Therapeutics, Inc. (the “Company”) increased its size to provide for a total of ten directors authorized to serve on the Board and appointed Claire Fraser, Ph.D. as a Class II director of the Company.”

Seres Therapeutics, Inc. amended First Amendment to Lease with BMR-Sidney Research Campus LLC (effective 2022-12-09).

“On December 9, 2022, Seres Therapeutics, Inc. (the “Company”) entered into the First Amendment to Lease (the “First Amendment”) with BMR-Sidney Research Campus LLC (f/k/a BMR 200-Sidney Street LLC), a Delaware limited liability company (the “Landlord”), which amends the Lease Agreement, dated November 11, 2015”

Seres Therapeutics, Inc. reported financial results for third quarter 2022.

“Seres Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022 and provided operational updates.”